Malaria poses a threat to nearly half of the world’s population, and recent literature in the USA is lacking regarding understanding risk for local outbreaks. This article aims to review Anopheles mosquito data, vector-borne disease outbreak preparedness, and human travel data from large international gateway cities in an effort to examine risk for localized outbreaks.
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients.
Date: 25 April 2013
Location: EmeryStation Greenway Building, 5800 Hollis St. Emeryville, CA
Deadline for Abstract Submission: 8 April 2013
NEW AFRICAN MALARIA COALITION MEETS IN MANHATTAN, NEW YORK CITY